S-1: Tivic Health Files S-1 for Resale of Common Stock

Tivic Health Systems, Inc. has filed an S-1 registration statement to allow for the resale of up to 956,222 shares of its common stock by Tumim Stone Capital, LLC.

Summary

• Tivic Health Systems, Inc. is filing a Form S-1 registration statement to permit Tumim Stone Capital, LLC (Tumim) to resell up to 956,222 shares of the company's common stock.
• These shares include 519,210 shares that Tivic may sell to Tumim under a Common Stock Purchase Agreement dated February 6, 2026, and 437,012 shares issuable upon exercise of a pre-funded warrant issued to Tumim on the same date.
• Tivic Health is not selling any securities in this offering and will not receive proceeds from Tumim's resale of shares. However, Tivic may receive up to $50.0 million in gross proceeds from future sales of its common stock to Tumim under the purchase agreement.
• The company has undergone a strategic transformation, pivoting from a diversified bioelectronic medical device company to a focused biopharmaceutical company centered on its lead program, Entolimod, a TLR5 agonist for Acute Radiation Syndrome (ARS) and oncology indications.
• Tivic Health also established Velocity Bioworks, a subsidiary contract development and manufacturing organization (CDMO), in December 2025.
• The company has implemented two reverse stock splits: a 1-for-17 split effective March 7, 2025, and a 1-for-100 split effective August 23, 2023.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the significant dilution risk for existing shareholders from the equity line of credit with Tumim, the company's ongoing concerns about its ability to continue as a going concern, and the lack of current revenue-generating products.

Positives

• Tivic Health has secured exclusive worldwide license rights and options for Entolimod and its second-generation compound, Entolasta.
• Entolimod has received Fast Track and Orphan Drug designations from the FDA for ARS.
• The company has established Velocity Bioworks, a CDMO subsidiary, to de-risk its Entolimod commercialization plan and create a new revenue vertical.
• Entolimod has a substantial preclinical and clinical data package supported by $140 million in prior capital, including $35.6 million in non-dilutive funding from government agencies.
• The company is exploring international market opportunities for Entolimod's emergency use prior to U.S. commercialization.

Negatives

• The issuance of common stock to Tumim may cause substantial dilution to existing stockholders.
• The sale of shares by Tumim could cause the price of Tivic Health's common stock to decline.
• It is not possible to predict the actual number of shares Tivic will sell to Tumim or the gross proceeds from those sales.
• The terms of the Purchase Agreement limit the amount of shares Tivic may issue to Tumim, potentially restricting its ability to enhance cash resources.
• Investors who buy shares at different times will likely pay different prices, leading to varied investment outcomes and potential dilution.
• The company has incurred charges related to the wind-down of its consumer business and expects additional costs.
• The company's financial statements include an explanatory paragraph describing conditions that raise substantial doubt about its ability to continue as a going concern.

Risks

• The actual number of shares sold to Tumim and the resulting gross proceeds are unpredictable.
• The Purchase Agreement's limitations on share issuance may restrict Tivic's ability to raise capital.
• Future equity offerings could lead to additional dilution for existing stockholders.
• Management has broad discretion over the use of proceeds from sales to Tumim, and these proceeds may not be invested successfully.
• The market price of the common stock could decline if Tumim sells a substantial number of shares.
• The company may need to obtain stockholder approval to issue shares beyond the Exchange Cap, as required by Nasdaq rules.
• The company may be required to utilize more costly and time-consuming means of accessing capital markets if limitations prevent selling the full committed amount to Tumim.
• The company's ability to continue as a going concern is subject to substantial doubt, as noted by its independent auditors.

Future Outlook

The company is focused on advancing Entolimod through regulatory approval for ARS and into government procurement, as well as expanding its oncology indications. It also aims to leverage Velocity Bioworks for internal manufacturing and external CDMO services. The company anticipates using proceeds from potential sales to Tumim for general corporate purposes, including operating expenses, capital expenditures, and working capital.

Management Comments

• The company has executed a deliberate and material strategic transformation, pivoting from a diversified bioelectronic medical device company to a focused biopharmaceutical company built around the TLR5 agonist franchise.
• Velocity Bioworks serves a dual strategic purpose: it de-risks our Entolimod commercialization plan by providing internal control over the manufacturing and validation timeline, and it creates a new vertical revenue by offering specialized services to external partners.
• We believe these anti-apoptotic and prophylactic properties position our TLR5 agonists as compelling alternatives or adjunctive therapies to currently marketed G-CSF treatments.

Industry Context

StockSavvy.ai notes that Tivic Health's strategic pivot to a biopharmaceutical focus, particularly on Entolimod for ARS and oncology, aligns with trends in the development of novel therapeutics for unmet medical needs, especially those with potential government procurement applications. The establishment of an in-house CDMO capability is also a strategic move seen in companies aiming for greater control over manufacturing and supply chains.

Stakeholder Impact

• Existing shareholders may experience significant dilution in their ownership percentage and potential decline in share price due to the resale of shares by Tumim and potential future equity issuances.
• Investors purchasing shares from Tumim may pay different prices, leading to varied investment outcomes.
• Employees may be impacted by the company's strategic pivot and the wind-down of certain business segments.

Next Steps

• Tumim Stone Capital, LLC may offer and resell up to 956,222 shares of Tivic Health's common stock.
• Tivic Health may sell shares to Tumim under the Purchase Agreement from time to time.
• The company will continue to advance Entolimod through regulatory approval for ARS and explore oncology indications.
• Velocity Bioworks will continue to develop its CDMO services.

Key Dates

Recommendation

The filing indicates a strategic shift towards a biopharmaceutical focus with a promising lead candidate (Entolimod) that has received FDA designations. However, the significant dilution risk from the equity line of credit with Tumim, coupled with the company's going concern issues, necessitates a cautious approach. While the long-term potential exists, the immediate risks warrant a 'hold' recommendation until clarity emerges on the commercialization of Entolimod and the impact of ongoing financing activities on shareholder value.

Keywords

Tivic Health Systems, S-1 Filing, Registration Statement, Common Stock, Tumim Stone Capital, Entolimod, Acute Radiation Syndrome, Biopharmaceutical, CDMO, Velocity Bioworks, Nasdaq, Dilution, Capital Raise